Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

2.0K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urinary metabolomics reveals potential biomarkers for monitoring carbon black exposure-related airway injury.

Frontiers in public health·2026
Same author

Th1/Th17-Treg Imbalance in Asian Atrial Fibrillation: Subtype and Demographic Heterogeneity.

JACC. Asia·2026
Same author

Four-in-one multifunctional CoCu-NC@AuPt nanozyme integrated M13 phage-displayed nanobody based multimodal lateral flow immunoassay for bovine lactoferrin detection.

Biosensors & bioelectronics·2026
Same author

Application of personalized nursing based on dynamic monitoring of oral pH in oral management of patients with hematological diseases undergoing chemotherapy.

Scientific reports·2026
Same author

A mouse model of mechanical stress injury to the basal ganglia using thermosensitive PNIPAM hydrogel for intracerebral hemorrhage research.

Animal models and experimental medicine·2026
Same author

A closed-loop myocardial infarction theranostic platform activated by macrophage-derived nitric oxide and acidic microenvironment.

Bioactive materials·2026

Related Experiment Video

Updated: Jun 21, 2025

Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes
11:47

Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes

Published on: March 4, 2022

2.2K

Urinary complement factor D is increased in primary malignant hypertension: a single-center, cross-sectional study.

Yaqi Cheng1, Weiwei Qin2,3, Liling Lin4

  • 1Department of Nephrology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100730, China.

Scientific Reports
|July 15, 2024
PubMed
Summary

Researchers identified urinary complement factor D (CFD) as a potential non-invasive biomarker for kidney damage in primary malignant hypertension (pMHTN). Elevated CFD levels may indicate alternative complement pathway activation in pMHTN patients.

Keywords:
Complement factor DMalignant hypertensionUrinary biomarker

More Related Videos

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:25

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.8K
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.2K

Related Experiment Videos

Last Updated: Jun 21, 2025

Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes
11:47

Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes

Published on: March 4, 2022

2.2K
Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:25

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.8K
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.2K

Area of Science:

  • Nephrology
  • Biochemistry
  • Proteomics

Background:

  • Kidney injury is a serious complication of primary malignant hypertension (pMHTN).
  • Non-invasive biomarkers are needed for diagnosing pMHTN-related renal damage and understanding its mechanisms.
  • Urine protein analysis offers a promising avenue for biomarker discovery.

Purpose of the Study:

  • To identify and validate urinary protein biomarkers for renal damage associated with pMHTN.
  • To explore the diagnostic potential of these biomarkers in differentiating pMHTN from other conditions.

Main Methods:

  • Discovery phase: In-gel digestion coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS) on urine samples from pMHTN patients, disease controls (DCs), and healthy controls (HCs).
  • Validation phase: Enzyme-linked immunosorbent assay (ELISA) to quantify differentially expressed proteins in a larger cohort.
  • Receiver operating characteristic (ROC) curve analysis to assess diagnostic performance.

Main Results:

  • LC-MS/MS identified 5 differentially expressed proteins in pMHTN patients.
  • Urinary complement factor D (CFD) was significantly upregulated in pMHTN patients compared to DCs and HCs.
  • Urinary CFD/Creatinine ratio demonstrated moderate potential in discriminating pMHTN from DCs (AUC = 0.822).

Conclusions:

  • Urinary CFD is a potential non-invasive biomarker for renal damage in pMHTN.
  • Elevated urinary CFD suggests activation of the alternative complement pathway in pMHTN.
  • Further research is warranted to confirm CFD's clinical utility in pMHTN management.